Novartis Gene Therapies is Drug Discovery in United States that focus on gene therapies business. Founded in 2010. They cover business area such as developer, gene therapy, rare and orphan neurological genetic disease, spinal muscular atrophy, (SMA, Type, an autosomal-recessive genetic disorder, low motor neuron loss and progressive muscle weakness, patient, family, treatment, life-threaten genetic disease.
2010
( 14 years old in 2024 )
Gene Therapies
-
2275 Half Day Road
Suite 203
Bannockburn, IL 60015
United States
Private
developergene therapyrare and orphan neurological genetic diseasespinal muscular atrophy(SMATypean autosomal-recessive genetic disorderlow motor neuron loss and progressive muscle weaknesspatientfamilytreatmentlife-threaten genetic disease
* We use standard office opening hours in near Novartis Gene Therapies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Novartis Gene Therapies is Drug Discovery business from United States that founded in 2010 (14 years old in 2024), Novartis Gene Therapies business is focusing on Gene Therapies.
Novartis Gene Therapies headquarter office and corporate office address is located in 2275 Half Day Road Suite 203 Bannockburn, IL 60015 United States.
Novartis Gene Therapies was founded in United States.
In 2024, Novartis Gene Therapies is currently focus on gene therapies sector.
Above is snippet of Google Trends for "gene therapies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Novartis Gene Therapies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
